Inhaled tobramycin: Not just for cystic fibrosis anymore?

Chest

Volumn 127, Issue 4, 2005, Pages 1098-1101

  LoBue, Philip A ^a,b  

^a Centers for Disease Control and Prevention ^*

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; BRONCHIECTASIS; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG USE; DYSPNEA; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HEARING LOSS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; OTOTOXICITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TINNITUS; TREATMENT OUTCOME; VOICE CHANGE; WHEEZING; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; MICROBIOLOGY; NOTE;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 19044385015     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.4.1098     Document Type: Editorial

References (23)

1. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; NIH Publication No. 97-4051
2. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmomol 1992; 12:158-161
3. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30
4. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001; 17:93-96
5. Hudson ME, Penketh ARL, Batten IC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 2:1137-1139
6. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984; 20:43-45
7. Wall MA, Terry AB, Eisenberg J, et al. Inhaled antibiotics in cystic fibrosis [letter]. Lancet 1983; 1:1325
8. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19:831-838
9. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989; 6:91-98
10. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120(suppl): 107s-113s
11. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219-226
12. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63:2501-2520
13. Hoffmann IM, Rubin BK, Iskandar SS, et al. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002; 34:375-377
14. Edson RS, Brey RH, McDonald TJ, et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004; 79:1185-1191
15. Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002; 122:930-934
16. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002; 20:122-126
17. Burns JL, Van Dalfsen JM, Shawar RM et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-1196
18. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55-63
19. Lin HC, Cheng HF, Wang CH, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997; 155:2024-2029
20. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481-485
21. Orriols R, Roig J, Ferrer J et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999; 93:476-480
22. Hofmann T, Otto K, Kirihara J, et al. Safety and tolerability of aztreonam for inhalation in healthy volunteers [abstract]. Pediatr Pulmonol 2003; 25(suppl):A338
23. Conley J, Yang H, Wilson T, et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997; 41:1288-1292